EGFR Amplification clinical trials at UC Cancer
1 research study open to eligible people
Showing trials for
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
open to eligible people ages 18 years and up
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
at UCLA UCSD
Our lead scientists for EGFR Amplification research studies include Deborah Wong, MD Assuntina Sacco, MD.